TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• TransMedics Group, Inc. has received an average rating of "Moderate Buy" from analysts, with a target price of $123.00.
• Insider trading activity includes Director David Weill selling 732 shares and Edward M. Basile selling 6,000 shares, resulting in a significant decrease in their ownership positions.
• TransMedics reported a strong performance in its latest earnings, with earnings per share of $0.92 and revenue growth of 37.7% compared to the previous year.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) has been given an average rating of "Moderate Buy" by the nine brokerages that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $123.00.

A number of analysts recently issued reports on the stock. Wall Street Zen upgraded shares of TransMedics Group from a "hold" rating to a "buy" rating in a research report on Saturday. Oppenheimer raised their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Piper Sandler restated an "overweight" rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Morgan Stanley raised their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Finally, Canaccord Genuity Group increased their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th.

Insiders Place Their Bets

In other news, Director David Weill sold 732 shares of the firm's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director owned 12,134 shares of the company's stock, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the transaction, the director directly owned 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,418 shares of company stock valued at $1,512,613 over the last quarter. Company insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in TransMedics Group by 244.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock worth $209,448,000 after buying an additional 2,209,996 shares during the period. FIL Ltd increased its stake in TransMedics Group by 28.0% during the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock worth $62,372,000 after buying an additional 218,961 shares during the period. Braidwell LP purchased a new stake in TransMedics Group during the 4th quarter worth $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in TransMedics Group by 16.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock worth $56,307,000 after buying an additional 128,474 shares during the period. Finally, Mackenzie Financial Corp increased its stake in TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock worth $51,635,000 after buying an additional 349,403 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Down 2.1%

TMDX stock opened at $125.74 on Wednesday. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $177.37. The company's 50 day simple moving average is $124.54 and its 200-day simple moving average is $96.21. The firm has a market capitalization of $4.29 billion, a PE ratio of 65.15 and a beta of 2.09. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. During the same quarter last year, the business earned $0.35 earnings per share. TransMedics Group's revenue was up 37.7% compared to the same quarter last year. Equities analysts expect that TransMedics Group will post 1 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.